Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 52,600 | 107,200 | 56,000 | 68,000 | -190,600 |
| Depreciation Amortization | 105,600 | 79,500 | 53,600 | 27,700 | 116,200 |
| Income taxes - deferred | -4,000 | -5,500 | 4,700 | 18,600 | -5,500 |
| Accounts receivable | 25,500 | -26,400 | 45,200 | -73,300 | -24,400 |
| Accounts payable and accrued liabilities | -8,400 | -19,800 | -15,800 | -5,400 | -33,000 |
| Other Working Capital | -25,500 | -106,700 | -24,600 | -119,500 | 85,100 |
| Other Operating Activity | 24,800 | 64,600 | -23,900 | 72,700 | 110,900 |
| Operating Cash Flow | $170,600 | $92,900 | $95,200 | $-11,200 | $58,700 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 24,400 | 28,300 | 31,700 | 34,500 | -15,000 |
| Net Acquisitions | N/A | N/A | N/A | N/A | 110,200 |
| Other Investing Activity | 45,000 | 45,000 | 45,000 | 25,000 | 30,000 |
| Investing Cash Flow | $69,400 | $73,300 | $76,700 | $59,500 | $125,200 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 0 | 0 | 284,000 |
| Debt Repayment | -108,700 | -6,900 | 0 | 0 | -482,400 |
| Common Stock Issued | 2,200 | 1,000 | N/A | N/A | 22,700 |
| Common Stock Repurchased | -24,900 | -15,800 | -6,900 | N/A | N/A |
| Other Financing Activity | -5,200 | -1,000 | 100 | -400 | -14,300 |
| Financing Cash Flow | $-136,600 | $-22,700 | $-6,800 | $-400 | $-190,000 |
| Exchange Rate Effect | 100 | 100 | 300 | -700 | N/A |
| Beginning Cash Position | 105,600 | 105,600 | 105,600 | 105,600 | 111,700 |
| End Cash Position | 209,100 | 249,200 | 271,000 | 152,800 | 105,600 |
| Net Cash Flow | $103,500 | $143,600 | $165,400 | $47,200 | $-6,100 |
| Free Cash Flow | |||||
| Operating Cash Flow | 170,600 | 92,900 | 95,200 | -11,200 | 58,700 |
| Capital Expenditure | -13,800 | -9,900 | -6,500 | -3,600 | -22,900 |
| Free Cash Flow | 156,800 | 83,000 | 88,700 | -14,800 | 35,800 |